Trial Outcomes & Findings for Evaluation of AMG 714 for Vitiligo (NCT NCT04338581)

NCT ID: NCT04338581

Last Updated: 2026-04-21

Results Overview

An F-VASI35 responder is defined as a participant who has at least 35% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at Week 24 are imputed as F-VASI35 non-responders.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

60 participants

Primary outcome timeframe

Week 24

Results posted on

2026-04-21

Participant Flow

Seven sites in the United States were activated. All seven sites randomized participants. The first site was activated in November 2020 and the last participant was randomized in May 2024.

Participant milestones

Participant milestones
Measure
AMG 714
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Overall Study
STARTED
40
20
Overall Study
Received AMG 714
40
1
Overall Study
Received Placebo
0
19
Overall Study
COMPLETED
34
16
Overall Study
NOT COMPLETED
6
4

Reasons for withdrawal

Reasons for withdrawal
Measure
AMG 714
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Overall Study
Lack of Efficacy
1
0
Overall Study
Withdrawal by Subject
4
4
Overall Study
Prohibited Medication
1
0

Baseline Characteristics

Evaluation of AMG 714 for Vitiligo

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Total
n=59 Participants
Total of all reporting groups
Age, Continuous
49.9 Years
STANDARD_DEVIATION 12.75 • n=13 Participants
52.4 Years
STANDARD_DEVIATION 14.40 • n=13 Participants
50.7 Years
STANDARD_DEVIATION 13.23 • n=26 Participants
Sex: Female, Male
Female
19 Participants
n=13 Participants
9 Participants
n=13 Participants
28 Participants
n=26 Participants
Sex: Female, Male
Male
21 Participants
n=13 Participants
10 Participants
n=13 Participants
31 Participants
n=26 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=13 Participants
2 Participants
n=13 Participants
7 Participants
n=26 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
35 Participants
n=13 Participants
16 Participants
n=13 Participants
51 Participants
n=26 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=13 Participants
1 Participants
n=13 Participants
1 Participants
n=26 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=13 Participants
0 Participants
n=13 Participants
0 Participants
n=26 Participants
Race (NIH/OMB)
Asian
3 Participants
n=13 Participants
3 Participants
n=13 Participants
6 Participants
n=26 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=13 Participants
0 Participants
n=13 Participants
0 Participants
n=26 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=13 Participants
1 Participants
n=13 Participants
4 Participants
n=26 Participants
Race (NIH/OMB)
White
27 Participants
n=13 Participants
12 Participants
n=13 Participants
39 Participants
n=26 Participants
Race (NIH/OMB)
More than one race
4 Participants
n=13 Participants
0 Participants
n=13 Participants
4 Participants
n=26 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=13 Participants
3 Participants
n=13 Participants
6 Participants
n=26 Participants
Region of Enrollment
United States
40 participants
n=13 Participants
19 participants
n=13 Participants
59 participants
n=26 Participants
Vitiligo Type at Baseline
Active Vitiligo
23 Participants
n=13 Participants
11 Participants
n=13 Participants
34 Participants
n=26 Participants
Vitiligo Type at Baseline
Stable Vitiligo
17 Participants
n=13 Participants
8 Participants
n=13 Participants
25 Participants
n=26 Participants
F-VASI at Baseline
1.154 Score on a Scale
STANDARD_DEVIATION 0.8982 • n=13 Participants
1.035 Score on a Scale
STANDARD_DEVIATION 0.9513 • n=13 Participants
1.116 Score on a Scale
STANDARD_DEVIATION 0.9091 • n=26 Participants
T-VASI at Baseline
19.901 Score on a Scale
STANDARD_DEVIATION 21.4012 • n=13 Participants
18.884 Score on a Scale
STANDARD_DEVIATION 15.0015 • n=13 Participants
19.573 Score on a Scale
STANDARD_DEVIATION 19.4434 • n=26 Participants

PRIMARY outcome

Timeframe: Week 24

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

An F-VASI35 responder is defined as a participant who has at least 35% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at Week 24 are imputed as F-VASI35 non-responders.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24
0.150 Proportion of participants
Interval 0.057 to 0.298
0.053 Proportion of participants
Interval 0.001 to 0.26

SECONDARY outcome

Timeframe: Weeks 12, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

An F-VASI35 responder is defined as a participant who has at least 35% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at any visit are imputed as F-VASI35 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Weeks 12, 36, 48.
Week 12
0.100 Proportion of participants
Interval 0.028 to 0.237
0.105 Proportion of participants
Interval 0.013 to 0.331
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Weeks 12, 36, 48.
Week 36
0.375 Proportion of participants
Interval 0.227 to 0.542
0.105 Proportion of participants
Interval 0.013 to 0.331
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Weeks 12, 36, 48.
Week 48
0.400 Proportion of participants
Interval 0.249 to 0.567
0.263 Proportion of participants
Interval 0.091 to 0.512

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

An F-VASI25 responder is defined as a participant who has at least 25% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at any visit are imputed as F-VASI25 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI25) at Weeks 12, 24, 36, 48.
Week 48
0.525 Proportion of participants
Interval 0.361 to 0.685
0.474 Proportion of participants
Interval 0.244 to 0.711
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI25) at Weeks 12, 24, 36, 48.
Week 12
0.200 Proportion of participants
Interval 0.091 to 0.356
0.105 Proportion of participants
Interval 0.013 to 0.331
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI25) at Weeks 12, 24, 36, 48.
Week 24
0.150 Proportion of participants
Interval 0.057 to 0.298
0.053 Proportion of participants
Interval 0.001 to 0.26
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI25) at Weeks 12, 24, 36, 48.
Week 36
0.475 Proportion of participants
Interval 0.315 to 0.639
0.316 Proportion of participants
Interval 0.126 to 0.566

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo

An F-VASI50 responder is defined as a participant who has at least 50% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at any visit are imputed as F-VASI50 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI50) at Weeks 12, 24, 36, 48
Week 12
0.050 Proportion of participants
Interval 0.006 to 0.169
0.053 Proportion of participants
Interval 0.001 to 0.26
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI50) at Weeks 12, 24, 36, 48
Week 24
0.075 Proportion of participants
Interval 0.016 to 0.204
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI50) at Weeks 12, 24, 36, 48
Week 36
0.300 Proportion of participants
Interval 0.166 to 0.465
0.053 Proportion of participants
Interval 0.001 to 0.26
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI50) at Weeks 12, 24, 36, 48
Week 48
0.350 Proportion of participants
Interval 0.206 to 0.517
0.263 Proportion of participants
Interval 0.091 to 0.512

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

An F-VASI75 responder is defined as a participant who has at least 75% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at any visit are imputed as F-VASI75 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) at Weeks 12, 24, 36, 48
Week 12
0.025 Proportion of participants
Interval 0.001 to 0.132
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) at Weeks 12, 24, 36, 48
Week 36
0.100 Proportion of participants
Interval 0.028 to 0.237
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) at Weeks 12, 24, 36, 48
Week 48
0.200 Proportion of participants
Interval 0.091 to 0.356
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

An F-VASI90 responder is defined as a participant who has at least 90% improvement from Baseline in the facial vitiligo area scoring index (F-VASI). F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. Participants missing the F-VASI assessment at any visit are imputed as F-VASI90 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI90) at Weeks 12, 24, 36, 48
Week 48
0.075 Proportion of participants
Interval 0.016 to 0.204
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI90) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI90) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI90) at Weeks 12, 24, 36, 48
Week 36
0.025 Proportion of participants
Interval 0.001 to 0.132
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

A T-VASI25 responder is defined as a participant who has at least 25% improvement from Baseline in the total body vitiligo area scoring index (T-VASI). T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. Participants missing the T-VASI assessment at any visit are imputed as T-VASI25 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI25) at Weeks 12, 24, 36, 48
Week 24
0.075 Proportion of participants
Interval 0.016 to 0.204
0.053 Proportion of participants
Interval 0.001 to 0.26
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI25) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.053 Proportion of participants
Interval 0.001 to 0.26
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI25) at Weeks 12, 24, 36, 48
Week 36
0.100 Proportion of participants
Interval 0.028 to 0.237
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 25% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI25) at Weeks 12, 24, 36, 48
Week 48
0.325 Proportion of participants
Interval 0.186 to 0.491
0.105 Proportion of participants
Interval 0.013 to 0.331

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

A T-VASI35 responder is defined as a participant who has at least 35% improvement from Baseline in the total body vitiligo area scoring index (T-VASI). T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. Participants missing the T-VASI assessment at any visit are imputed as T-VASI35 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI35) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI35) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI35) at Weeks 12, 24, 36, 48
Week 36
0.075 Proportion of participants
Interval 0.016 to 0.204
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI35) at Weeks 12, 24, 36, 48
Week 48
0.275 Proportion of participants
Interval 0.146 to 0.439
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

A T-VASI50 responder is defined as a participant who has at least 50% improvement from Baseline in the total body vitiligo area scoring index (T-VASI). T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. Participants missing the T-VASI assessment at any visit are imputed as T-VASI50 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) at Weeks 12, 24, 36, 48
Week 36
0.025 Proportion of participants
Interval 0.001 to 0.132
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) at Weeks 12, 24, 36, 48
Week 48
0.150 Proportion of participants
Interval 0.057 to 0.298
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

A T-VASI75 responder is defined as a participant who has at least 75% improvement from Baseline in the total body vitiligo area scoring index (T-VASI). T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. Participants missing the T-VASI assessment at any visit are imputed as T-VASI75 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) at Weeks 12, 24, 36, 48
Week 36
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) at Weeks 12, 24, 36, 48
Week 48
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

A T-VASI90 responder is defined as a participant who has at least 90% improvement from Baseline in the total body vitiligo area scoring index (T-VASI). T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. Participants missing the T-VASI assessment at any visit are imputed as T-VASI90 non-responders for that visit.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) at Weeks 12, 24, 36, 48
Week 12
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) at Weeks 12, 24, 36, 48
Week 24
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) at Weeks 12, 24, 36, 48
Week 36
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176
Proportion of Participants Achieving a ≥ 90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) at Weeks 12, 24, 36, 48
Week 48
0.000 Proportion of participants
Interval 0.0 to 0.088
0.000 Proportion of participants
Interval 0.0 to 0.176

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. A negative change from Baseline in the F-VASI signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 12
-0.053 Score on a scale
Interval -0.167 to 0.06
-0.060 Score on a scale
Interval -0.232 to 0.113
Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 48
-0.343 Score on a scale
Interval -0.535 to -0.152
-0.133 Score on a scale
Interval -0.412 to 0.146
Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 24
0.047 Score on a scale
Interval -0.113 to 0.207
0.091 Score on a scale
Interval -0.152 to 0.333
Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 36
-0.221 Score on a scale
Interval -0.387 to -0.056
-0.048 Score on a scale
Interval -0.307 to 0.211

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. A negative change from Baseline in the T-VASI signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 12
0.325 Score on a Scale
Interval -0.196 to 0.845
-0.049 Score on a Scale
Interval -0.838 to 0.74
Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 24
0.339 Score on a Scale
Interval -0.71 to 1.388
0.582 Score on a Scale
Interval -1.007 to 2.171
Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 36
-0.447 Score on a Scale
Interval -1.733 to 0.839
1.000 Score on a Scale
Interval -1.008 to 3.008
Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 48
-3.007 Score on a Scale
Interval -5.508 to -0.506
-1.590 Score on a Scale
Interval -5.236 to 2.055

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

The Vitiligo Extent Score (VES) is a tool for measuring the total body surface area affected by vitiligo. Images are shown of varying extent of vitiligo lesions from least to greatest extent over different body locations. An image from each body location is selected by the investigator during the patient encounter that best reflects the extent to which vitiligo lesions are covering the body surface area (BSA). If lesions are covering an area larger than shown in the last photo, a \>75% but \<100% option can be selected. The online calculator at www.vitiligo-calculator.com will then use selected images to calculate the percentage of the body surface area involved or grade of extent per region (Grade 0 to 6). The VES has a possible range from 0 to 100, with higher scores indicating more severe disease. A negative change from Baseline in the VES signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Change From Baseline in the Vitiligo Extent Score (VES) at Weeks 12, 24, 36, 48
Week 12
-1.194 Score on a scale
Interval -2.353 to -0.036
-0.166 Score on a scale
Interval -1.925 to 1.593
Change From Baseline in the Vitiligo Extent Score (VES) at Weeks 12, 24, 36, 48
Week 24
-0.710 Score on a scale
Interval -2.019 to 0.6
0.157 Score on a scale
Interval -1.832 to 2.146
Change From Baseline in the Vitiligo Extent Score (VES) at Weeks 12, 24, 36, 48
Week 36
-1.935 Score on a scale
Interval -3.645 to -0.225
0.661 Score on a scale
Interval -2.015 to 3.337
Change From Baseline in the Vitiligo Extent Score (VES) at Weeks 12, 24, 36, 48
Week 48
-4.634 Score on a scale
Interval -6.866 to -2.403
-1.571 Score on a scale
Interval -4.831 to 1.689

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

The Vitiligo-specific Health-related Quality-of-life Instrument (VitiQoL) is a validated instrument that asks participants to rate various aspects of their vitiligo during the past month. The response to each question will be scored on a 0 (not at all) to 6 (all of the time) scale. The VitiQoL score is calculated as the sum of questions 1 through 15, providing a possible range from 0 to 90, with higher scores indicating more severe disease. A negative change from Baseline in the VitiQoL signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Change From Baseline in the Vitiligo-specific Health-related Quality-of-life Instrument (VitiQoL) Score at Weeks 12, 24, 36, 48
Week 48
1.7 Score on a scale
Interval -3.8 to 7.2
-4.9 Score on a scale
Interval -13.0 to 3.1
Change From Baseline in the Vitiligo-specific Health-related Quality-of-life Instrument (VitiQoL) Score at Weeks 12, 24, 36, 48
Week 36
3.2 Score on a scale
Interval -1.4 to 7.8
2.8 Score on a scale
Interval -4.4 to 10.1
Change From Baseline in the Vitiligo-specific Health-related Quality-of-life Instrument (VitiQoL) Score at Weeks 12, 24, 36, 48
Week 12
0.1 Score on a scale
Interval -3.5 to 3.7
-0.8 Score on a scale
Interval -6.2 to 4.6
Change From Baseline in the Vitiligo-specific Health-related Quality-of-life Instrument (VitiQoL) Score at Weeks 12, 24, 36, 48
Week 24
1.5 Score on a scale
Interval -2.9 to 5.8
-1.4 Score on a scale
Interval -8.0 to 5.2

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

The Vitiligo Noticeability Scale (VNS) is a validated patient-reported outcome measure of vitiligo treatment where participants will be presented with one pre-treatment photograph of their face and asked to answer the question: "Compared with before treatment, how noticeable is the vitiligo now?". The same pre-treatment photograph must be used at each visit. Scores range from 1 to 5 with a score of 1 being "More noticeable", 2 "As noticeable", 3 "Slightly less noticeable", 4 "A lot less noticeable", and 5 "No longer noticeable". Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 48 A lot less noticeable
0.118 Proportion of participants
0.188 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 24 A lot less noticeable
0.026 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 24 No longer noticeable
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 36 More noticeable
0.179 Proportion of participants
0.250 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 36 As noticeable
0.564 Proportion of participants
0.563 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 36 Slightly less noticeable
0.205 Proportion of participants
0.125 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 36 A lot less noticeable
0.051 Proportion of participants
0.063 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 36 No longer noticeable
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 48 More noticeable
0.235 Proportion of participants
0.188 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 48 As noticeable
0.382 Proportion of participants
0.375 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 48 No longer noticeable
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 48 Slightly less noticeable
0.265 Proportion of participants
0.250 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 12 More noticeable
0.128 Proportion of participants
0.294 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 12 As noticeable
0.744 Proportion of participants
0.706 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 12 No longer noticeable
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 12 Slightly less noticeable
0.128 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 12 A lot less noticeable
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 24 Slightly less noticeable
0.026 Proportion of participants
0.059 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 24 More noticeable
0.103 Proportion of participants
0.294 Proportion of participants
Proportion of Participants in Each Vitiligo Noticeability Scale (VNS) Category at Weeks 12, 24, 36, 48
Week 24 As noticeable
0.846 Proportion of participants
0.647 Proportion of participants

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

The Static Investigator Global Assessment (sIGA) is a 5-point scale that grades the loss of pigmentation and severity of lesions on a participant's body. Lower scores represent lesser extent and lesser severity; higher scores represent greater extent and greater severity. A score of 0 represents clear skin, with no loss of pigmentation after a natural light or Woods lamp examination and a score of 4 represents severe vitiligo, with extensive loss of pigmentation affecting most areas of the body. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=40 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=19 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 12 Clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Baseline Almost clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Baseline Mild vitiligo
0.175 Proportion of participants
0.053 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Baseline Moderate vitiligo
0.575 Proportion of participants
0.474 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Baseline Severe vitiligo
0.250 Proportion of participants
0.474 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 12 Almost clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 36 Severe vitiligo
0.256 Proportion of participants
0.375 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 24 Severe vitiligo
0.359 Proportion of participants
0.471 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 36 Clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 48 Clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 48 Almost clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 48 Severe vitiligo
0.206 Proportion of participants
0.313 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Baseline Clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 12 Mild vitiligo
0.077 Proportion of participants
0.059 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 12 Moderate vitiligo
0.513 Proportion of participants
0.529 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 12 Severe vitiligo
0.410 Proportion of participants
0.412 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 24 Clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 24 Almost clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 24 Mild vitiligo
0.077 Proportion of participants
0.118 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 24 Moderate vitiligo
0.564 Proportion of participants
0.412 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 36 Almost clear
0.000 Proportion of participants
0.000 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 36 Mild vitiligo
0.128 Proportion of participants
0.063 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 36 Moderate vitiligo
0.615 Proportion of participants
0.563 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 48 Mild vitiligo
0.235 Proportion of participants
0.063 Proportion of participants
Shifts From Baseline in the Distribution of Static Investigator Global Assessment (sIGA) Scores at Weeks 12, 24, 36, 48
Week 48 Moderate vitiligo
0.559 Proportion of participants
0.625 Proportion of participants

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

F-VASI assesses the area of the face affected by vitiligo. F-VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. F-VASI has a possible range from 0 to 3.5, with higher scores indicating more severe disease. A negative percent change from Baseline in the F-VASI signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Percent Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 24
17.397 Percent change
Interval -5.545 to 40.339
26.041 Percent change
Interval -8.762 to 60.845
Percent Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 12
1.673 Percent change
Interval -8.314 to 11.66
-2.052 Percent change
Interval -17.202 to 13.098
Percent Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 36
-10.907 Percent change
Interval -33.511 to 11.696
11.360 Percent change
Interval -23.962 to 46.682
Percent Change From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Weeks 12, 24, 36, 48
Week 48
-20.429 Percent change
Interval -46.958 to 6.1
-3.897 Percent change
Interval -42.605 to 34.811

SECONDARY outcome

Timeframe: Baseline; Weeks 12, 24, 36, and 48

Population: The Modified Intent-to-Treat (mITT) population included all randomized participants who received at least one dose of either AMG 714 or placebo.

T-VASI assesses the area of the body affected by vitiligo. The body is divided into 6 regions: head and neck, upper extremities, hands, torso, lower extremities, and feet. For each body region, the VASI is determined by the product of the percent of vitiligo involvement (percent of body surface area \[BSA\]) and the degree of depigmentation estimated to the nearest of the following percentages: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The percentage of BSA (hand or thumb unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator. T-VASI is derived by summing the values of all body regions, providing a possible range from 0 to 99, with higher scores indicating more severe disease. A negative percent change from Baseline in the T-VASI signifies improvement. Only participants with available data were analyzed.

Outcome measures

Outcome measures
Measure
AMG 714
n=39 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=17 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Percent Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 12
2.515 Percent change
Interval -1.787 to 6.816
-2.418 Percent change
Interval -8.935 to 4.099
Percent Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 24
2.385 Percent change
Interval -4.2 to 8.971
3.604 Percent change
Interval -6.373 to 13.581
Percent Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 36
-1.175 Percent change
Interval -8.456 to 6.107
7.876 Percent change
Interval -3.492 to 19.245
Percent Change From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI) at Weeks 12, 24, 36, 48
Week 48
-15.510 Percent change
Interval -25.386 to -5.633
-1.178 Percent change
Interval -15.576 to 13.221

SECONDARY outcome

Timeframe: Week 0 to Week 24, Week 0 to Week 48

Population: The Safety population included all participants for whom study treatment was initiated. Safety analyses are based on the actual treatment the participants received. Any participant receiving at least one injection of AMG 714 at any time during the study will be summarized with the AMG 714 treatment arm. One participant randomized to the placebo group received AMG 714.

A participant who experienced any Grade 2 or higher treatment-emergent adverse event. Includes all ≥ Grade 2 untoward or unfavorable medical occurrence(s) associated with investigational product administration or any study mandated procedures.

Outcome measures

Outcome measures
Measure
AMG 714
n=41 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=18 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants With a Grade 2 or Higher Treatment-Emergent Adverse Event
Week 0 to Week 24
0.439 Proportion of participants
0.333 Proportion of participants
Proportion of Participants With a Grade 2 or Higher Treatment-Emergent Adverse Event
Week 0 to Week 48
0.561 Proportion of participants
0.444 Proportion of participants

SECONDARY outcome

Timeframe: Week 0 to Week 24, Week 0 to Week 48

Population: The Safety population included all participants for whom study treatment was initiated. Safety analyses are based on the actual treatment the participants received. Any participant receiving at least one injection of AMG 714 at any time during the study will be summarized with the AMG 714 treatment arm. One participant randomized to the placebo group received AMG 714.

A participant who experienced any Grade 3 or higher infectious treatment-emergent adverse event. Includes all ≥ Grade 3 infectious untoward or unfavorable medical occurrence(s).

Outcome measures

Outcome measures
Measure
AMG 714
n=41 Participants
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Placebo
n=18 Participants
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Proportion of Participants With a Grade 3 or Higher Infectious Treatment-Emergent Adverse Event
Week 0 to Week 24
0.000 Proportion of participants
0.000 Proportion of participants
Proportion of Participants With a Grade 3 or Higher Infectious Treatment-Emergent Adverse Event
Week 0 to Week 48
0.000 Proportion of participants
0.000 Proportion of participants

Adverse Events

AMG 714

Serious events: 0 serious events
Other events: 23 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
AMG 714
n=41 participants at risk
Participants receive 300 mg AMG 714 subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10. Any participant receiving at least one injection of AMG 714 at any time during the study will be summarized with the AMG 714 treatment arm.
Placebo
n=18 participants at risk
Participants receive placebo subcutaneously every 2 weeks for 6 doses beginning at Week 0 with the last dose at Week 10.
Blood and lymphatic system disorders
Anaemia
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Blood and lymphatic system disorders
Leukopenia
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Blood and lymphatic system disorders
Neutropenia
7.3%
3/41 • Number of events 5 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Eye disorders
Ocular discomfort
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Gastrointestinal disorders
Gastrooesophageal reflux disease
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Gastrointestinal disorders
Inguinal hernia
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
General disorders
Asthenia
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
General disorders
Fatigue
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
General disorders
Hypothermia
4.9%
2/41 • Number of events 2 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
General disorders
Influenza like illness
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
COVID-19
7.3%
3/41 • Number of events 3 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
11.1%
2/18 • Number of events 2 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Gastrointestinal bacterial overgrowth
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Gastrointestinal infection
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Helicobacter infection
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Nasopharyngitis
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Postoperative wound infection
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Infections and infestations
Sinusitis
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Exposure to toxic agent
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Joint injury
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Limb injury
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Nail injury
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Radiation injury
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Rib fracture
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Injury, poisoning and procedural complications
Scapula fracture
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Aspartate aminotransferase increased
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Blood albumin decreased
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Blood bilirubin increased
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Lymphocyte count decreased
4.9%
2/41 • Number of events 3 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Neutrophil count decreased
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Weight decreased
4.9%
2/41 • Number of events 2 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Investigations
Weight increased
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Metabolism and nutrition disorders
Dehydration
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Metabolism and nutrition disorders
Hyperlipidaemia
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoid tumour
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Nervous system disorders
Headache
2.4%
1/41 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
0.00%
0/18 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Skin and subcutaneous tissue disorders
Actinic keratosis
0.00%
0/41 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
5.6%
1/18 • Number of events 1 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
Vascular disorders
Hypertension
7.3%
3/41 • Number of events 3 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.
11.1%
2/18 • Number of events 2 • Treatment-emergent adverse events were recorded in EDC from after treatment initiation at Week 0 to Week 48.
Generalized pruritus or urticaria Grade 1 hypersensitivity/anaphylaxis reactions, confirmed Grade 1 SARS-CoV-2 infections, and Grade 2 or higher AEs were recorded in EDC. Safety analyses are based on the safety population, which consists of all participants who receive any amount of AMG 714 or placebo. Participants will be analyzed according to the actual treatment received. One participant randomized to the placebo group received AMG 714.

Additional Information

Director, Clinical Research Operations Program

DAIT/NIAID

Phone: 301-594-7669

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place